Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid (EPA) - Intervention Trial).
|Headquarters||2 Pembroke House|
Upper Pembroke Street 28-32, Dublin 2
DUBLIN, CT, Ireland 06355
|Chairman of the Board, Chief Executive Officer||Joseph Zakrzewski|
|President, Principal Financial Officer, Assistant Secretary||John Thero|
|President - Research and Development, Senior Vice President||Steven Ketchum|
|Senior Vice President, Chief Compliance Officer, General Counsel, Secretary||Joseph Kennedy|
|Senior Vice President, Chief Commercial Officer||Paul Huff|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||150.7M||Book Value||$-0.03|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||--|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||--|
*GAAP = prior to non-GAAP analyst adjusted earnings.